Objective: To compare the risk and cost of stroke/systemic embolism (SE) and major
bleeding between each direct oral anticoagulant (DOAC) and warfarin among non-valvular …

Purpose This study aimed to evaluate the cost-effectiveness of dabigatran and rivaroxaban
compared with warfarin for the prevention of stroke in patients with atrial fibrillation (AF) in …

Background—Sex-specific comparative effectiveness of direct oral anticoagulants among
patients with nonvalvular atrial fibrillation is not known. Via this retrospective cohort study …

Background Understanding the value of new anticoagulation therapies compared with
existing therapies is of paramount importance in today's cost-conscious and efficiency …

Objective: To compare the risk of stroke/systemic embolism (S/SE) and major bleeding (MB)
of elderly (≥ 65 years of age) nonvalvular atrial fibrillation (NVAF) patients initiating …

Atrial fibrillation is the most common arrhythmia in clinical practice, and age is one of the
strongest predictors/risk factors for ischemic stroke in patients with atrial fibrillation. Elderly …

Aims Elderly atrial fibrillation (AF) patients with risk factors of bleeding are often considered
ineligible for standard oral anticoagulants (OACs). The Edoxaban Low-Dose for EldeR …

Objective To estimate the quality‐adjusted life‐years (QALY s), costs, and cost‐effectiveness
of high‐dose edoxaban compared with adjusted‐dose warfarin in patients at risk for stroke …

Approximately 250,000 Canadians are affected by atrial fibrillation (AF). Stroke is a
complication of AF, and Canadians with AF are five times more likely to have a stroke and …

It remains unknown whether the comparative effectiveness of direct oral anticoagulants
(DOACs) and warfarin differs between atrial fibrillation patients with and without a history of …